Sonnet BioTherapeutics is no longer just a cancer drug developer. Its $888 million merger will place it among the largest HYPE holders, blurring the lines between traditional finance and decentralized protocols in a high-stakes treasury experiment. According to a July…
Related Posts
Smart contract blockchains will become less cypherpunk, says VC boss
Jesse Walden, managing partner at Variant Fund, says the original cypherpunk values that influenced early blockchains could fade…
Bitcoin outlook shifts as Bitfinex alpha warns etf flows now ‘dominate’ price
Bitfinex Alpha says weakening demand, macro headwinds and a turn in spot ETF flows now “dominate” Bitcoin’s price…
Crypto’s next big opportunity: Invisible finance interfaces | Opinion
Great interfaces where crypto becomes invisible are what will onboard the next billion users, leading to a long-awaited…